The literature on the use of e-stim for treating neuropathy symptoms demonstrates the capability of the modality to alter nerve injury or neuropathy: in diabetes, nerve damage has been associated with microvascular disease to the nerve, and cutaneous circulation significantly increases with the application of e-stim, as well as vascular endothelial growth factor (a primary angiogenic factor) [24–27]. Here, VEGFA is linked to neuropathy.